Tiny study probes why some MS patients react to their medication
NCT ID NCT06310343
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed study involved 15 people with relapsing-remitting multiple sclerosis who were already taking alemtuzumab. Researchers measured anti-drug antibodies in their blood over 24 months to see if these antibodies affect treatment or cause infusion reactions. The goal was to better understand how the body responds to the drug, not to test a new therapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- alemtuzumab
- What this could lead to
- If successful, this could help doctors understand why some MS patients have infusion reactions to alemtuzumab and how to manage treatment better.
- What could go wrong
- This is a very small, completed observational study with only 15 participants, so results may not apply to all MS patients. It does not test a new treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Barts Health NHS Trust
London, Second Floor Neurophys Dept, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can we decode the different types of pain in multiple sclerosis?
- Can a blood pressure pill slow MS disability?
- Hidden MS progression: can brain scans and blood tests predict it?
- Can Brain-Training apps fix sleep in MS?
- Can an Iron-Based dye reveal hidden inflammation in progressive MS?
- Strumming for the brain: could ukulele lessons sharpen minds in MS?